# FIERCE-22 (NCT03123055)

> A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03123055
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Rainier Therapeutics
- Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma; Urinary Bladder Disease; Urological Diseases
- Interventions: B-701; Pembrolizumab
- Enrollment: 28
- Primary outcome: Number of Participants With Dose Limiting Toxicities Within a Period of 35 Days
- Primary outcome: Number of Subjects Experiencing Adverse Events (AEs and SAEs)
- Primary outcome: Efficacy of B-701 (Vofatamab) Plus Pembrolizumab Measured by ORR

## Indexed commentary on FIERCE-22 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fierce-22-nct03123055